Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging

Fig. 5

The ability of 30 ELISA-validated urine proteins to discriminate bladder cancer patients by their disease stage. A Thirty urinary proteins were assayed by ELISA, using the UTSW cohort, comprised of 7 MIBC and 30 NMIBC subjects. The ELISA results for MIBC vs NMIBC are displayed. Biomarker protein units (normalized to creatinine) are as follows: n = ng/mg, p = pg/mg. Specificity.0.8 depicts the specificity at a fixed sensitivity of 0.8. Indicated are the statistical significance p-values as determined by a Mann-Whitney U-test *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. B The dot plots depict the 8 proteins with the highest AUC value for MIBC vs NMIBC comparison. Tested samples include 30 NMIBC (10 Ta, 10 Tis, 10 T1) and 7 MIBC (T2–T4). Creatine-normalized urine protein levels are shown in different colors representing UC, NMIBC, and MIBC. The asterisks indicate the level of significance between the groups: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page